BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that CEO Stephen Dilly, M.B.B.S., Ph.D., will present at the 18th Annual BIO CEO & Investor Conference in New York City on Monday, February 8, 2016, at 9:00 a.m. Eastern Time.
